Predicting Postoperative Chemotherapy Efficacy in Patients With Esophageal Squamous Cell Carcinoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age20+
SponsorCity of Hope Medical Center
About this trial
Esophageal cancer remains a disease with a poor prognosis. Chemotherapy is an important part of its treatment, but there are cases in which chemotherapy is ineffective. The investigators aim to develop a model to predict the response to chemotherapy by DNA methylation of preoperative biopsy specimens to identify the chemotherapy ineffective group.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients who had histologically confirmed esophageal squamous cell carcinoma.
Patients who had undergone chemotherapy.
Patients receiving initial chemotherapy
Written informed consent following full study information is provided to the patient.
Disqualifiers
Patients for whom a preoperative biopsy sample cannot be obtained
Patients who cannot assess at 2 months later after chemotherapy.
Patients with multiple cancers.
Trial population
Chemotherapy naive patient needed esophageal squamous cell carcinoma chemotherapy
Trial design
Design model
Case-control
Time perspective
Cross-sectional
Treatments tested in this trial
Fluoro Uracil
DrugEsophageal cancer chemotherapy（First line treatment)
Treatment groups
150 Participants
are divided into 2 treatment groupsGroup A: Chemotherapy response patients.1 intervention
Group B: Chemotherapy non-response patients1 intervention
Trial outcomes
Primary outcomes
1
Overall response rate(Chemotherapy)
The effect of initial chemotherapy is evaluated by imaging. Response evaluation criteria in solid tumors (RECIST) is used for treatment efficacy.
Time frame
1yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov